Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , , , , , , , |
---|---|
Format: | Elektronisch E-Book |
Sprache: | English |
Veröffentlicht: |
Erlangen
Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)
2016
|
Schlagworte: | |
Online-Zugang: | Volltext Volltext Volltext |
Beschreibung: | Aus: Annals of Oncology 25.7 (2014): S. 1428-1436. <http://annonc.oxfordjournals.org/content/25/7/1428.abstract> Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. This publication is with permission of the rights owner freely accessible due to an Alliance licence or a national licence (funded by the DFG, German Research Foundation) respectively. |
Beschreibung: | 1 Online-Ressource |
Format: | Langzeitarchivierung gewährleistet, LZA |
Internformat
MARC
LEADER | 00000nmm a2200000zc 4500 | ||
---|---|---|---|
001 | BV043793630 | ||
003 | DE-604 | ||
005 | 00000000000000.0 | ||
007 | cr|uuu---uuuuu | ||
008 | 160926s2016 gw |||| o||u| ||||||eng d | ||
015 | |a 16,O10 |2 dnb | ||
016 | 7 | |a 111329065X |2 DE-101 | |
024 | 7 | |a urn:nbn:de:bvb:29-opus4-74190 |2 urn | |
035 | |a (OCoLC)959652120 | ||
035 | |a (DE-599)DNB111329065X | ||
040 | |a DE-604 |b ger |e rda | ||
041 | 0 | |a eng | |
044 | |a gw |c XA-DE-BY | ||
049 | |a DE-29 | ||
082 | 0 | |a 610 |2 23 | |
084 | |a 610 |2 sdnb | ||
100 | 1 | |a Grob, J.-J. |e Verfasser |4 aut | |
245 | 1 | 0 | |a Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma |b quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine |c J.-J. Grob ; M. M. Amonkar ; S. Martin-Algarra ; L. V. Demidov ; V. Goodman ; K. Grotzinger ; P. Haney ; E. Kämpgen ; B. Karaszewska ; C. Mauch ; W. H. Miller Jr. ; M. Millward ; B. Mirakhur ; P. Rutkowski ; V. Chiarion-Sileni ; S. Swann ; A. Hauschild |
264 | 1 | |a Erlangen |b Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) |c 2016 | |
300 | |a 1 Online-Ressource | ||
336 | |b txt |2 rdacontent | ||
337 | |b c |2 rdamedia | ||
338 | |b cr |2 rdacarrier | ||
500 | |a Aus: Annals of Oncology 25.7 (2014): S. 1428-1436. <http://annonc.oxfordjournals.org/content/25/7/1428.abstract> | ||
500 | |a Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. | ||
500 | |a This publication is with permission of the rights owner freely accessible due to an Alliance licence or a national licence (funded by the DFG, German Research Foundation) respectively. | ||
538 | |a Langzeitarchivierung gewährleistet, LZA | ||
653 | |a melanoma | ||
653 | |a quality of life | ||
653 | |a dabrafenib | ||
653 | |a chemotherapy | ||
700 | 1 | |a Amonkar, M. M. |e Verfasser |4 aut | |
700 | 1 | |a Martin-Algarra, S. |e Verfasser |4 aut | |
700 | 1 | |a Demidov, L. V. |e Verfasser |4 aut | |
700 | 1 | |a Goodman, V. |e Verfasser |4 aut | |
700 | 1 | |a Grotzinger, K. |e Verfasser |4 aut | |
700 | 1 | |a Haney, P. |e Verfasser |4 aut | |
700 | 1 | |a Kämpgen, E. |e Verfasser |4 aut | |
700 | 1 | |a Karaszewska, B. |e Verfasser |4 aut | |
700 | 1 | |a Mauch, C. |e Verfasser |4 aut | |
700 | 1 | |a Miller Jr., W. H. |e Verfasser |4 aut | |
700 | 1 | |a Millward, M. |e Verfasser |4 aut | |
700 | 1 | |a Mirakhur, B. |e Verfasser |4 aut | |
700 | 1 | |a Rutkowski, P. |e Verfasser |4 aut | |
700 | 1 | |a Chiarion-Sileni, V. |e Verfasser |4 aut | |
700 | 1 | |a Swann, S. |e Verfasser |4 aut | |
700 | 1 | |a Hauschild, A. |e Verfasser |4 aut | |
856 | 4 | 0 | |u https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-74190 |x Resolving-System |z kostenfrei |3 Volltext |
856 | 4 | 0 | |u http://d-nb.info/111329065X/34 |x Langzeitarchivierung Nationalbibliothek |z kostenfrei |3 Volltext |
856 | 4 | 0 | |u https://open.fau.de/handle/openfau/7419 |x Verlag |z kostenfrei |3 Volltext |
912 | |a ebook | ||
999 | |a oai:aleph.bib-bvb.de:BVB01-029204558 |
Datensatz im Suchindex
_version_ | 1804176635163836416 |
---|---|
any_adam_object | |
author | Grob, J.-J Amonkar, M. M. Martin-Algarra, S. Demidov, L. V. Goodman, V. Grotzinger, K. Haney, P. Kämpgen, E. Karaszewska, B. Mauch, C. Miller Jr., W. H. Millward, M. Mirakhur, B. Rutkowski, P. Chiarion-Sileni, V. Swann, S. Hauschild, A. |
author_facet | Grob, J.-J Amonkar, M. M. Martin-Algarra, S. Demidov, L. V. Goodman, V. Grotzinger, K. Haney, P. Kämpgen, E. Karaszewska, B. Mauch, C. Miller Jr., W. H. Millward, M. Mirakhur, B. Rutkowski, P. Chiarion-Sileni, V. Swann, S. Hauschild, A. |
author_role | aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
author_sort | Grob, J.-J |
author_variant | j j g jjg m m a mm mma s m a sma l v d lv lvd v g vg k g kg p h ph e k ek b k bk c m cm j w h m jwh jwhm m m mm b m bm p r pr v c s vcs s s ss a h ah |
building | Verbundindex |
bvnumber | BV043793630 |
collection | ebook |
ctrlnum | (OCoLC)959652120 (DE-599)DNB111329065X |
dewey-full | 610 |
dewey-hundreds | 600 - Technology (Applied sciences) |
dewey-ones | 610 - Medicine and health |
dewey-raw | 610 |
dewey-search | 610 |
dewey-sort | 3610 |
dewey-tens | 610 - Medicine and health |
discipline | Medizin |
format | Electronic eBook |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02982nmm a2200649zc 4500</leader><controlfield tag="001">BV043793630</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">160926s2016 gw |||| o||u| ||||||eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">16,O10</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">111329065X</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">urn:nbn:de:bvb:29-opus4-74190</subfield><subfield code="2">urn</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)959652120</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB111329065X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BY</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Grob, J.-J.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma</subfield><subfield code="b">quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine</subfield><subfield code="c">J.-J. Grob ; M. M. Amonkar ; S. Martin-Algarra ; L. V. Demidov ; V. Goodman ; K. Grotzinger ; P. Haney ; E. Kämpgen ; B. Karaszewska ; C. Mauch ; W. H. Miller Jr. ; M. Millward ; B. Mirakhur ; P. Rutkowski ; V. Chiarion-Sileni ; S. Swann ; A. Hauschild</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Erlangen</subfield><subfield code="b">Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU)</subfield><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Aus: Annals of Oncology 25.7 (2014): S. 1428-1436. <http://annonc.oxfordjournals.org/content/25/7/1428.abstract></subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">This publication is with permission of the rights owner freely accessible due to an Alliance licence or a national licence (funded by the DFG, German Research Foundation) respectively.</subfield></datafield><datafield tag="538" ind1=" " ind2=" "><subfield code="a">Langzeitarchivierung gewährleistet, LZA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">melanoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">quality of life</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">dabrafenib</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemotherapy</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Amonkar, M. M.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Martin-Algarra, S.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Demidov, L. V.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goodman, V.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Grotzinger, K.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haney, P.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kämpgen, E.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Karaszewska, B.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mauch, C.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miller Jr., W. H.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Millward, M.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mirakhur, B.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rutkowski, P.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Chiarion-Sileni, V.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Swann, S.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hauschild, A.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-74190</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://d-nb.info/111329065X/34</subfield><subfield code="x">Langzeitarchivierung Nationalbibliothek</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://open.fau.de/handle/openfau/7419</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ebook</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029204558</subfield></datafield></record></collection> |
id | DE-604.BV043793630 |
illustrated | Not Illustrated |
indexdate | 2024-07-10T07:35:19Z |
institution | BVB |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029204558 |
oclc_num | 959652120 |
open_access_boolean | 1 |
owner | DE-29 |
owner_facet | DE-29 |
physical | 1 Online-Ressource |
psigel | ebook |
publishDate | 2016 |
publishDateSearch | 2016 |
publishDateSort | 2016 |
publisher | Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) |
record_format | marc |
spelling | Grob, J.-J. Verfasser aut Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine J.-J. Grob ; M. M. Amonkar ; S. Martin-Algarra ; L. V. Demidov ; V. Goodman ; K. Grotzinger ; P. Haney ; E. Kämpgen ; B. Karaszewska ; C. Mauch ; W. H. Miller Jr. ; M. Millward ; B. Mirakhur ; P. Rutkowski ; V. Chiarion-Sileni ; S. Swann ; A. Hauschild Erlangen Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) 2016 1 Online-Ressource txt rdacontent c rdamedia cr rdacarrier Aus: Annals of Oncology 25.7 (2014): S. 1428-1436. <http://annonc.oxfordjournals.org/content/25/7/1428.abstract> Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich. This publication is with permission of the rights owner freely accessible due to an Alliance licence or a national licence (funded by the DFG, German Research Foundation) respectively. Langzeitarchivierung gewährleistet, LZA melanoma quality of life dabrafenib chemotherapy Amonkar, M. M. Verfasser aut Martin-Algarra, S. Verfasser aut Demidov, L. V. Verfasser aut Goodman, V. Verfasser aut Grotzinger, K. Verfasser aut Haney, P. Verfasser aut Kämpgen, E. Verfasser aut Karaszewska, B. Verfasser aut Mauch, C. Verfasser aut Miller Jr., W. H. Verfasser aut Millward, M. Verfasser aut Mirakhur, B. Verfasser aut Rutkowski, P. Verfasser aut Chiarion-Sileni, V. Verfasser aut Swann, S. Verfasser aut Hauschild, A. Verfasser aut https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-74190 Resolving-System kostenfrei Volltext http://d-nb.info/111329065X/34 Langzeitarchivierung Nationalbibliothek kostenfrei Volltext https://open.fau.de/handle/openfau/7419 Verlag kostenfrei Volltext |
spellingShingle | Grob, J.-J Amonkar, M. M. Martin-Algarra, S. Demidov, L. V. Goodman, V. Grotzinger, K. Haney, P. Kämpgen, E. Karaszewska, B. Mauch, C. Miller Jr., W. H. Millward, M. Mirakhur, B. Rutkowski, P. Chiarion-Sileni, V. Swann, S. Hauschild, A. Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine |
title | Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine |
title_auth | Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine |
title_exact_search | Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine |
title_full | Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine J.-J. Grob ; M. M. Amonkar ; S. Martin-Algarra ; L. V. Demidov ; V. Goodman ; K. Grotzinger ; P. Haney ; E. Kämpgen ; B. Karaszewska ; C. Mauch ; W. H. Miller Jr. ; M. Millward ; B. Mirakhur ; P. Rutkowski ; V. Chiarion-Sileni ; S. Swann ; A. Hauschild |
title_fullStr | Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine J.-J. Grob ; M. M. Amonkar ; S. Martin-Algarra ; L. V. Demidov ; V. Goodman ; K. Grotzinger ; P. Haney ; E. Kämpgen ; B. Karaszewska ; C. Mauch ; W. H. Miller Jr. ; M. Millward ; B. Mirakhur ; P. Rutkowski ; V. Chiarion-Sileni ; S. Swann ; A. Hauschild |
title_full_unstemmed | Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine J.-J. Grob ; M. M. Amonkar ; S. Martin-Algarra ; L. V. Demidov ; V. Goodman ; K. Grotzinger ; P. Haney ; E. Kämpgen ; B. Karaszewska ; C. Mauch ; W. H. Miller Jr. ; M. Millward ; B. Mirakhur ; P. Rutkowski ; V. Chiarion-Sileni ; S. Swann ; A. Hauschild |
title_short | Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma |
title_sort | patient perception of the benefit of a braf inhibitor in metastatic melanoma quality of life analyses of the break 3 study comparing dabrafenib with dacarbazine |
title_sub | quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine |
url | https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-74190 http://d-nb.info/111329065X/34 https://open.fau.de/handle/openfau/7419 |
work_keys_str_mv | AT grobjj patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine AT amonkarmm patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine AT martinalgarras patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine AT demidovlv patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine AT goodmanv patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine AT grotzingerk patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine AT haneyp patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine AT kampgene patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine AT karaszewskab patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine AT mauchc patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine AT millerjrwh patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine AT millwardm patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine AT mirakhurb patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine AT rutkowskip patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine AT chiarionsileniv patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine AT swanns patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine AT hauschilda patientperceptionofthebenefitofabrafinhibitorinmetastaticmelanomaqualityoflifeanalysesofthebreak3studycomparingdabrafenibwithdacarbazine |